Member Info for Marty130

I will never reveal the amount I paid.. That's for me and the missus to know..

Over exposed!! No I bought in sub 5p.

No, I am invested on a long position, won't be selling until later in 2027, if hvivo doesn't take part in a merger, which is entirely possible, under this CEO.

Well its definitely trending in the right direction, and without news.. Can't see any evidence for a pump & dump. So it suggests to me, investors are confident.

I suspect we are now heading towards 12p. Good to see positive sentiment returning, even without news.. We have a brilliant CEO, a man who knows the markets very well.. Expect new contracts to be announced in the coming weeks or months, or even a a merger.

Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona.

Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US.

He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems.

Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has "an established network of healthcare institutions already utilising its precision medicine solutions."

He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would "deliver long-term value for shareholders," despite lengthy implementation processes common across major US providers.

Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate "meaningful testing volumes" over time.

The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest.

Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years.

Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes.

While acknowledging that timing of commercial outcomes "remains difficult to predict," he said the board was confident that the company's current initiatives "position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders."

Renalytix said it would provide a trading update for the six months to 31 December by the end of January.

On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.

Great opportunity to buy into a company with a decent track record. The 7 million loss will be written off, and the company will move on. Spain is and always will be corrupt, having experienced it personally. The Spanish legal system is an enigma.

Cut n paste!

Us biotech 2026

AI Mode

All

Images

News

Videos

Shopping

Short videos

Maps

Forums

Books

Web

Flights

Finance

Search tools

Feedback

AI Overview

+4

US Biotech in 2026 is set for a strong rebound driven by innovation in areas like obesity, oncology, gene therapy, and AI, with significant M&A activity expected as big pharma seeks late-stage assets, though regulatory clarity and funding stability remain key factors. Analysts highlight growth in diagnostics, novel modalities (ADCs, RNA), and focus on CNS, chronic, and rare diseases, with key companies like Denali Therapeutics, Nuvalent, and Vanda Pharmaceuticals facing major catalysts. National security concerns, via the NDAA, are also introducing new procurement restrictions and outbound investment controls.

Key Trends & Drivers for 2026

Innovation Focus: Oncology, obesity (Lilly/Novo Nordisk battle), Alzheimer's, genetic medicine, CNS disorders, I&I (Infections & Inflammation), and cell/gene therapies.

Technological Advancements: Molecular degraders, RNA therapies, next-gen bispecifics, radiopharmaceuticals, Antibody-Drug Conjugates (ADCs), and AI for drug discovery.

Market Activity: Expect a dual-track recovery with an IPO surge in diagnostics, increased M&A for validated late-stage assets, and continued investor interest.

AI Integration: Growing role in drug discovery, clinical development, and healthcare delivery, with valuations still maturing.

Agreed..

Oh why!

Huge volumes today, possibly institutional buying.

Has he resigned! Which would explain the rise.

Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..

Full results should be out soon, last year they were released on the 31st of December. With the wizkid ceo buying recently, would indicate the company expects to report positive results, and excellent prospects for 2026..

Cevo,

And don't forget the CE mark will have a transformation affect.

We could expect decent growth next year..

Why?

Thanks for confirming. Lol.. Let's hope we all do well next year, and see the back this dreadful government.